• Something wrong with this record ?

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

HA. Ghofrani, MA. Gomez Sanchez, M. Humbert, D. Pittrow, G. Simonneau, H. Gall, E. Grünig, H. Klose, M. Halank, D. Langleben, RJ. Snijder, P. Escribano Subias, LM. Mielniczuk, TJ. Lange, JL. Vachiéry, H. Wirtz, DS. Helmersen, I. Tsangaris, JA....

. 2021 ; 178 (-) : 106220. [pub] 20201112

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22004600

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. RESULTS: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial [CHEST-2]). CONCLUSION: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified.

2nd Department of Critical Care University Hospital Attikon National and Kapodistrian University of Athens Athens Greece

Alberta Health Services University of Calgary Calgary Alberta Canada

Bayer AG Global Development Global Medical Affairs Berlin Germany

Biomedical Research Networking Center on Respiratory Diseases Madrid Spain

Biomedical Research Networking Centre on Respiratory Diseases Spain

Center for Pulmonary Vascular Disease Jewish General Hospital McGill University Montreal Quebec Canada

Centre for Pulmonary Hypertension Thoraxclinic at Heidelberg University Hospital Heidelberg Germany

CIBER CV Hospital 12 de Octubre Madrid Spain

Clinic of Pulmonology University Hospital Zurich Zurich Switzerland

Département de Cardiologie Cliniques Universitaires de Bruxelles Hôpital Erasme Brussels Belgium

Department 3 of Internal Medicine and Cologne Cardiovascular Research Center Cologne University Heart Center Cologne Germany

Department of Cardiology 1 Aristotle University of Thessaloniki Thessaloniki Greece

Department of Cardiology and Angiology Faculty of Medicine Slovak Medical University and National Institute of Cardiovascular Diseases Bratislava Slovak Republic

Department of Cardiology Hospital 12 de Octubre Madrid Spain

Department of Internal Medicine 2 Division of Pneumology University Medical Center Regensburg Germany

Department of Medicine Department of Cardiovascular Medicine Charles University Prague Prague Czech Republic

Department of Pneumology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Pulmonology St Antonius Ziekenhuis Nieuwegein the Netherlands

Department of Respiratory Diseases University Hospitals of Leuven and Respiratory Division Department CHROMETA KU Leuven University of Leuven Leuven Belgium

Department of Respiratory Medicine and the German Center for Lung Research Hannover Medical School Hannover Germany

Department of Respiratory Medicine University of Leipzig Leipzig Germany

Division of Cardiology Department of Medicine University of Ottawa Heart Institute Ottawa Ontario Canada

German Rheumatism Research Center Berlin Leibniz Institute Berlin Germany

Hospital Clínic IDIBAPS University of Barcelona Barcelona Spain

Institute for Clinical Pharmacology Technical University Dresden Germany

Medical Clinic 1 Department of Pneumology University Hospital Carl Gustav Carus Dresden Germany

Member of the German Center for Lung Research Giessen Germany

Pulmonary Vascular Disease Unit Royal Papworth Hospital Cambridge UK

Respiratory Department Ramón y Cajal University Hospital Madrid Spain

Servicestelle für klinische Studien Krankenhaus der Elisabethinen Linz GmbH Linz Austria

Université Paris Saclay Inserm U999 Service de Pneumologie et Soins Intensifs Respiratoires Hôpital Bicêtre Le Kremlin Bicêtre France

Université Paris Sud Le Kremlin Bicêtre Service de Pneumologie Centre de Référence de l'Hypertension Pulmonaire Sévère DHU Thorax Innovation Hôpital Bicêtre Le Kremlin Bicêtre Paris France

University of Giessen and Marburg Lung Center Giessen Germany

VU Medisch Centrum Amsterdam the Netherlands

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004600
003      
CZ-PrNML
005      
20220127145125.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.rmed.2020.106220 $2 doi
035    __
$a (PubMed)33540340
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; Member of the German Center for Lung Research (DZL), Giessen, Germany. Electronic address: Ardeschir.Ghofrani@innere.med.uni-giessen.de
245    10
$a Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry / $c HA. Ghofrani, MA. Gomez Sanchez, M. Humbert, D. Pittrow, G. Simonneau, H. Gall, E. Grünig, H. Klose, M. Halank, D. Langleben, RJ. Snijder, P. Escribano Subias, LM. Mielniczuk, TJ. Lange, JL. Vachiéry, H. Wirtz, DS. Helmersen, I. Tsangaris, JA. Barberá, J. Pepke-Zaba, A. Boonstra, S. Rosenkranz, S. Ulrich, R. Steringer-Mascherbauer, M. Delcroix, P. Jansa, I. Šimková, G. Giannakoulas, J. Klotsche, E. Williams, C. Meier, MM. Hoeper, NEW COLLABORATORS LIST
520    9_
$a OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. RESULTS: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial [CHEST-2]). CONCLUSION: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified.
650    _2
$a senioři $7 D000368
650    _2
$a chronická nemoc $7 D002908
650    12
$a analýza dat $7 D000078332
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a plicní hypertenze $x farmakoterapie $x etiologie $7 D006976
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multicentrické studie jako téma $7 D015337
650    _2
$a prospektivní studie $7 D011446
650    _2
$a plicní embolie $x komplikace $x farmakoterapie $7 D011655
650    _2
$a pyrazoly $x škodlivé účinky $x terapeutické užití $7 D011720
650    _2
$a pyrimidiny $x škodlivé účinky $x terapeutické užití $7 D011743
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a recidiva $7 D012008
650    12
$a registrace $7 D012042
650    _2
$a bezpečnost $7 D012449
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gomez Sanchez, Miguel-Angel $u Respiratory Department, Ramón y Cajal University Hospital (IRYCIS), Madrid, Spain; Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), Spain
700    1_
$a Humbert, Marc $u Université Paris-Saclay, Inserm U999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
700    1_
$a Pittrow, David $u Institute for Clinical Pharmacology, Technical University, Dresden, Germany
700    1_
$a Simonneau, Gérald $u Université Paris-Sud, Le Kremlin-Bicêtre, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris, France
700    1_
$a Gall, Henning $u University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; Member of the German Center for Lung Research (DZL), Giessen, Germany
700    1_
$a Grünig, Ekkehard $u Centre for Pulmonary Hypertension, Thoraxclinic at Heidelberg University Hospital, Heidelberg, Germany
700    1_
$a Klose, Hans $u Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Halank, Michael $u Medical Clinic I, Department of Pneumology, University Hospital Carl Gustav Carus, Dresden, Germany
700    1_
$a Langleben, David $u Center for Pulmonary Vascular Disease, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
700    1_
$a Snijder, Repke J $u Department of Pulmonology, St Antonius Ziekenhuis, Nieuwegein, the Netherlands
700    1_
$a Escribano Subias, Pilar $u Department of Cardiology, Hospital 12 de Octubre, Madrid, Spain; CIBER-CV (CIBER of Cardiovascular Disease), Hospital 12 de Octubre, Madrid, Spain
700    1_
$a Mielniczuk, Lisa M $u Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
700    1_
$a Lange, Tobias J $u Department of Internal Medicine II, Division of Pneumology, University Medical Center, Regensburg, Germany
700    1_
$a Vachiéry, Jean-Luc $u Département de Cardiologie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium
700    1_
$a Wirtz, Hubert $u Department of Respiratory Medicine, University of Leipzig, Leipzig, Germany
700    1_
$a Helmersen, Douglas S $u Alberta Health Services, University of Calgary, Calgary, Alberta, Canada
700    1_
$a Tsangaris, Iraklis $u Second Department of Critical Care, University Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Barberá, Joan A $u Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain; Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain
700    1_
$a Pepke-Zaba, Joanna $u Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK
700    1_
$a Boonstra, Anco $u VU Medisch Centrum, Amsterdam, the Netherlands
700    1_
$a Rosenkranz, Stephan $u Department III of Internal Medicine and Cologne Cardiovascular Research Center (CCRC), Cologne University Heart Center, Cologne, Germany
700    1_
$a Ulrich, Silvia $u Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland
700    1_
$a Steringer-Mascherbauer, Regina $u Servicestelle für klinische Studien, Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria
700    1_
$a Delcroix, Marion $u Department of Respiratory Diseases, University Hospitals of Leuven, and Respiratory Division, Department CHROMETA, KU Leuven - University of Leuven, Leuven, Belgium
700    1_
$a Jansa, Pavel $u 2(nd) Department of Medicine, Department of Cardiovascular Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Šimková, Iveta $u Department of Cardiology and Angiology, Faculty of Medicine, Slovak Medical University & National Institute of Cardiovascular Diseases, Bratislava, Slovak Republic
700    1_
$a Giannakoulas, George $u Department of Cardiology I, Aristotle University of Thessaloniki, Thessaloniki, Greece
700    1_
$a Klotsche, Jens $u German Rheumatism Research Center Berlin, Leibniz Institute, Berlin, Germany
700    1_
$a Williams, Evgenia $u Bayer AG, Global Development, Global Medical Affairs, Berlin, Germany
700    1_
$a Meier, Christian $u Bayer AG, Global Development, Global Medical Affairs, Berlin, Germany
700    1_
$a Hoeper, Marius M $u Department of Respiratory Medicine and the German Center for Lung Research, Hannover Medical School, Hannover, Germany
710    2_
$a NEW COLLABORATORS LIST
773    0_
$w MED00004105 $t Respiratory medicine $x 1532-3064 $g Roč. 178, č. - (2021), s. 106220
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33540340 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145121 $b ABA008
999    __
$a ok $b bmc $g 1751914 $s 1155749
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 178 $c - $d 106220 $e 20201112 $i 1532-3064 $m Respiratory medicine $n Respir Med $x MED00004105
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options